Monograph
J05AF11 - Telbivudine |
Propably not porphyrinogenic |
PNP |
Side effects
Common adverse reactions of telbividune that can be confused with an acute porphyric attack are diarrhoea, nausea and abdominal pains. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Telbivudine is not metabolized by CYP450 enzymes and is not an inducer or mechanism-based inhibitor of CYP450 enzymes. No pharmacokinetic porphyrinogenic effects are suspected.
Chemical description
Synthetic thymidine nucleoside analogue
Therapeutic characteristics
Telbivudine is used in the treatment of chronic hepatitis B in adult patients with evidence of viral replication, and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. It is administered orally.
Metabolism and pharmacokinetics
Telmivudine is not a substrate, inhibitor or inducer of CYP450 enzymes (SPC). It is eliminated primarily by urinary secretion of unchanged drug (Lui 2008).
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | A review of telbivudine for the management of chronic hepatitis B virus infection.
Lui YY, Chan HL. Expert Opin Drug Metab Toxicol. 2008 Oct;4(10):1351-61. |
18798704 |
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). (Sebivo).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Belgium
United Kingdom
Denmark
Luxembourg© NAPOS 2024